Why Perfect B Is Evaluating AOD 9604: Our Clinical Perspective We began our internal evaluation of AOD 9604 in response to a consistent pattern we were seeing with patients in our South Florida practice: people who had experienced meaningful fat loss on GLP-1 medications, then plateaued or discontinued due to side effects, and were looking for a next option
The one human trial that will measure tolerability directly has not started reporting it is only recruiting (planned 2026), studies a topical gel on small standardized wounds , and lists safety as a secondary, not primary, outcome (NCT07437586)
If this occurs, the therapy is slowed down to accommodate
Boosting glutathione may provide many health benefits, including reduction of oxidative stress
Better sleep architecture: Patients on consistent therapy often report deeper, more restorative sleep, consistent with the role of GH in stage III/IV sleep
If youd like to discuss pricing, schedule a one-on-one consultation with us at About Face Skin Care